| ［1］ |
Crow MK. Long interspersed nuclear elements （LINE⁃1）: potential triggers of systemic autoimmune disease［J］. Autoimmunity, 2010,43（1）:7⁃16. doi: 10.3109/08916930903374865.
|
| ［2］ |
Jiang Y, Zong W, Ju S, et al. Promising member of the short interspersed nuclear elements （Alu elements）: mechanisms and clinical applications in human cancers［J］. J Med Genet, 2019,56（10）:639⁃645. doi: 10.1136/jmedgenet⁃2018⁃105761.
|
| ［3］ |
Song Y, Li X, Wei X, et al. Human endogenous retroviruses as biomedicine markers［J］. Virol Sin, 2021,36（5）:852⁃858. doi: 10.1007/s12250⁃021⁃00387⁃7.
|
| ［4］ |
Cervantes⁃Ayalc A, Ruiz Esparza⁃Garrido R, Velázquez⁃Flores MÁ. Long interspersed nuclear elements 1 （LINE1）: the chimeric transcript L1⁃MET and its involvement in cancer［J］. Cancer Genet, 2020,241:1⁃11. doi: 10.1016/j.cancergen.2019. 11.004.
|
| ［5］ |
Sciamanna I, De Luca C, Spadafora C. The reverse transcriptase encoded by LINE⁃1 retrotransposons in the genesis, progression, and therapy of cancer［J］. Front Chem, 2016,4:6. doi: 10.3389/fchem.2016.00006.
|
| ［6］ |
Baldwin ET, van Eeuwen T, Hoyos D, et al. Structures, functions and adaptations of the human LINE⁃1 ORF2 protein. Nature［J］. 2024,626（7997）:194⁃206. doi: 10.1038/s41586⁃023⁃06947⁃z.
|
| ［7］ |
Tanaka S, Ise W, Baba Y, et al. Silencing and activating anergic B cells［J］. Immunol Rev, 2022,307（1）:43⁃52. doi: 10.1111/imr. 13053.
|
| ［8］ |
Dörner T, Szelinski F, Lino AC, et al. Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus［J/OL］. RMD Open, 2020,6（2）:e001258. doi: 10.1136/ rmdopen⁃2020⁃001258.
|
| ［9］ |
Liu Y, Zhang Z, Kang Z, et al. Interleukin 4⁃driven reversal of self⁃reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus［J］. Ann Rheum Dis, 2023,82（11）:1444⁃1454. doi: 10.1136/ard⁃2023⁃224453.
|
| ［10］ |
Zecchini V, Paupe V, Herranz⁃Montoya I, et al. Fumarate induces vesicular release of mtDNA to drive innate immunity［J］. Nature, 2023,615（7952）:499⁃506. doi: 10.1038/s41586⁃023⁃05770⁃w.
|
| ［11］ |
Kancherla P, Daneshvar M, Sager RA, et al. Fumarate hydratase as a therapeutic target in renal cancer［J］. Expert Opin Ther Targets, 2020,24（9）:923⁃936. doi: 10.1080/14728222.2020.180 4862.
|
| ［12］ |
Cheng J, Liu Y, Yan J, et al. Fumarate suppresses B⁃cell activation and function through direct inactivation of LYN［J］. Nat Chem Biol, 2022,18（9）:954⁃962. doi: 10.1038/s41589⁃022⁃01052⁃0.
|
| ［13］ |
Zhao Y, Li Y, Zhao D, et al. Fumarate hydratase⁃specific T cell response in Chinese patients with autoimmune hepatitis［J］. Clin Res Hepatol Gastroenterol, 2018,42（4）:339⁃346. doi: 10.1016/j.clinre.2017.12.003.
|
| ［14］ |
Hooftman A, Peace CG, Ryan DG, et al. Macrophage fumarate hydratase restrains mtRNA⁃mediated interferon production［J］. Nature, 2023,615（7952）:490⁃498. doi: 10.1038/s41586⁃023⁃05720⁃6.
|
| ［15］ |
Hou Y, Wang L, Luo C, et al. Clinical characteristics of early⁃onset paediatric systemic lupus erythematosus in a single centre in China［J］. Rheumatology （Oxford）, 2023,62（10）:3373⁃3381. doi: 10.1093/rheumatology/kead086.
|
| ［16］ |
Crisafulli F, Andreoli L, Zucchi D, et al. Variations of C3 and C4 before and during pregnancy in systemic lupus erythematosus: association with disease flares and obstetric outcomes［J］. J Rheumatol, 2023,50（10）:1296⁃1301. doi: 10.3899/jrheum.2022⁃1135.
|
| ［17］ |
Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update［J］. Ann Rheum Dis, 2024,83（1）:15⁃29. doi: 10.1136/ard⁃2023⁃224762.
|
| ［18］ |
Wohlrab J, Kreft D. Niacinamide ⁃ mechanisms of action and its topical use in dermatology［J］. Skin Pharmacol Physiol, 2014,27（6）:311⁃315. doi: 10.1159/000359974.
|
| ［19］ |
Nouh AH, Elshahid AR, Kadah AS, et al. Topical niacinamide （nicotinamide） treatment for discoid lupus erythematosus （DLE）: a prospective pilot study［J］. J Cosmet Dermatol, 2023,22（5）:1647⁃1657. doi: 10.1111/jocd.15628.
|
| ［20］ |
Sterner RC, Sterner RM. CAR⁃T cell therapy: current limitations and potential strategies［J］. Blood Cancer J, 2021,11（4）:69. doi: 10.1038/s41408⁃021⁃00459⁃7.
|
| ［21］ |
Ying Z, Yang H, Guo Y, et al. Relmacabtagene autoleucel （relma⁃cel） CD19 CAR⁃T therapy for adults with heavily pretreated relapsed/refractory large B⁃cell lymphoma in China［J］. Cancer Med, 2021,10（3）:999⁃1011. doi: 10.1002/cam4.3686.
|
| ［22］ |
Ying Z, Yang H, Guo Y, et al. Long⁃term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B⁃cell lymphoma: updated results of the RELIANCE study［J］. Cytotherapy, 2023,25（5）:521⁃529. doi: 10.1016/j.jcyt.2022.10.011.
|
| ［23］ |
Lin Z, Zuo C, Jiang Y, et al. Cost⁃effectiveness analysis of relmacabtagene autoleucel for relapsed or refractory large B⁃cell lymphoma in China［J］. Value Health Reg Issues, 2023,37:41⁃48. doi: 10.1016/j.vhri.2023.03.006.
|
| ［24］ |
Hurst C, Soto M, Vina ER, et al. Renin⁃angiotensin system⁃modifying antihypertensive drugs can reduce the risk of cardiovascular complications in lupus: a retrospective cohort study［J］. Am J Med, 2023,136（3）:284⁃293.e4. doi: 10.1016/j.amjmed.2022.11.016.
|
| ［25］ |
Roccatello D, Fenoglio R, Caniggia I, et al. Daratumumab monotherapy for refractory lupus nephritis［J］. Nat Med, 2023,29（8）:2041⁃2047. doi: 10.1038/s41591⁃023⁃02479⁃1.
|
